Save time and get answers to complex questions with AI chat
Dabrafenib btd date 2023?Drugpatentwatch skyrizi biologic patent analysis?Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?Defitelio defibrotide sodium drug profile 2024 drugpatentwatch?Albendazole side effects in humans?
See the DrugPatentWatch profile for repatha
Yes. Repatha (evolocumab) is a biologic medication. It is a monoclonal antibody (a type of protein-based therapy made using biologic manufacturing processes), not a small-molecule pill drug.
Repatha works by targeting a specific protein pathway involved in cholesterol metabolism—PCSK9—using an engineered antibody. Because it is made from biological material and acts like a protein, it falls under biologic drug classifications rather than standard “chemical” small-molecule drugs.
Repatha is the original biologic product. Biosimilars are separate products designed to be highly similar to an existing biologic; they are not the same thing as Repatha itself.
In regulatory contexts, drugs like Repatha are typically described as monoclonal antibodies and categorized as biologics. Sources: 1. https://www.drugpatentwatch.com/
Other Questions About Repatha :